SRS Clinical Cancer Research Study for Brain Metastases

The American Society for Radiation Oncology (ASTRO) recently presented data from a study that may have determined a therapeutic advantage of stereotactic radiosurgery (SRS) over whole-brain radiation therapy (WBRT) in patients diagnosed with brain metastases.

The observational study presented at ASTRO’s 2013 annual meeting compared SRS to WBRT in 413 patients who were diagnosed with non-small cell lung cancer with fewer than four brain metastases. Researchers found that patients treated with SRS had an overall survival of nine months compared to 3.9 months for patients treated with WBRT.

Although the optimal treatment for brain metastases is currently unknown, the findings suggest that improved survival rates could be among the benefits that SRS offers to patients diagnosed with the disease. To read more about this study, click here.

Our center uses SRS to treat brain metastases using CyberKnife^® technology. SRS doesn’t require anesthesia and is an important alternative when patients are not candidates for traditional surgery.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.